GLP3-RT: The Triple-Agonist Metabolic Compound Explained
GLP3-RT (LY-3437943) is the first synthetic peptide engineered to hit three metabolic receptors at once — GLP-1, GIP, and glucagon — in a single molecule. Mono-agonists like semaglutide work one receptor. Dual agonists like tirzepatide work two. GLP3-RT works all three, and the Phase 2 data put it in the NEJM with the largest mean weight reduction ever reported for a single investigational agent.
The Quick Read
- GLP3-RT → triple-incretin receptor agonist (GLP-1R + GIPR + GCGR) on a single peptide backbone with a fatty-acid tail for once-weekly half-life.
- Primary research finding → 24.2% mean body weight reduction at the highest dose over 48 weeks (Jastreboff et al., 2023, NEJM), with up to 86% liver fat reduction.
- What sets it apart → adds glucagon-driven hepatic thermogenesis to incretin-driven appetite suppression. Most weight-loss compounds work intake. GLP3-RT also works expenditure.
- Purity → ≥99% HPLC-verified at Ki, with COA per batch. Research use only.
Why this compound is interesting
The incretin compound class has evolved in clear generations. Semaglutide hit GLP-1. Tirzepatide added GIP. Each generation produced a measurable jump in effect size, particularly on body weight and metabolic markers. GLP3-RT represents the next step — and the NEJM Phase 2 data suggest it is not just an incremental improvement but a qualitatively different mechanism.
The reason: glucagon. Adding glucagon receptor activation introduces hepatic thermogenesis and fat oxidation, which raises energy expenditure. Prior compounds reduced what went in. GLP3-RT also increases what gets burned. That two-lever mechanism is what produced the dramatic liver fat reductions and the new ceiling on weight-loss research endpoints.
What Is GLP3-RT?
GLP3-RT is a synthetic peptide with a molecular weight of approximately 4,600 Da (development code LY-3437943). It was designed by integrating agonist motifs for three distinct hormone receptors — GLP-1R, GIPR, and GCGR — into a single peptide backbone, then conjugating it with a fatty acid chain to extend its half-life. The result: a once-weekly research compound that hits three metabolic targets simultaneously.
The story behind GLP3-RT follows a clear evolutionary arc. First came the GLP-1 mono-agonists — compounds that activate one receptor to suppress appetite and improve insulin sensitivity. Then came the dual agonists, adding GIP receptor activation to amplify the incretin response. GLP3-RT takes the logical next step: layering glucagon receptor activation on top of GLP-1 and GIP.
Why glucagon? Because it unlocks the other side of the energy equation.
GLP-1 and GIP work primarily on the intake side — reducing appetite, slowing gastric emptying, and modulating insulin. Glucagon receptor activation works on the output side — driving hepatic thermogenesis, stimulating fat oxidation in the liver, and increasing resting energy expenditure. GLP3-RT was designed to pull both levers at once.
The compound first entered clinical literature through a Phase 1 trial published in The Lancet (Urva et al., 2022), followed by a landmark Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023). Phase 3 trials are currently ongoing. GLP3-RT has not received regulatory approval and is available strictly for research purposes only.
The Three Receptors: GLP-1R, GIPR, and GCGR
Each receptor contributes a different piece of the metabolic signal. Understand the three, and the compound's mechanism becomes obvious.
GLP-1 Receptor (GLP-1R)
GLP-1R is the most well-characterized incretin receptor in metabolic research. When activated, it:
- Suppresses appetite by acting on hypothalamic hunger circuits
- Enhances glucose-dependent insulin secretion from pancreatic beta cells
- Slows gastric emptying, reducing post-meal glucose spikes
- Reduces glucagon secretion during hyperglycemia (a paradox — more on this below)
This receptor is the foundation of the entire incretin agonist class. Semaglutide, liraglutide, and exenatide all target GLP-1R exclusively.
GIP Receptor (GIPR)
Glucose-dependent insulinotropic polypeptide receptor activation adds a second dimension:
- Amplifies insulin secretion in a glucose-dependent manner
- Modulates fat metabolism in adipose tissue
- Enhances bone formation through direct osteoblast signaling
- Complements GLP-1R activation for greater combined incretin effect
Tirzepatide was the first dual GLP-1R/GIPR agonist to demonstrate that adding GIP to GLP-1 produces outcomes exceeding GLP-1 alone. The GIP component appears to enhance the tolerability and efficacy ceiling of GLP-1 activation.
Glucagon Receptor (GCGR)
This is the differentiator. Glucagon receptor activation:
- Increases hepatic energy expenditure through thermogenesis
- Promotes fat oxidation directly in the liver
- Drives lipolysis — the breakdown of stored fat for fuel
- Raises resting metabolic rate, burning more calories at baseline
Adding GCGR agonism seems counterintuitive at first. Glucagon raises blood glucose — wouldn't activating it undermine the glucose-lowering effects of GLP-1 and GIP? In practice, the GLP-1R and GIPR activation more than compensate for glucagon's hyperglycemic effect. The net result in Phase 2 data was improved glucose control and increased energy expenditure — the best of both pathways.
Why Triple Agonism Matters
The jump from dual to triple is not just "more receptors." It introduces a fundamentally different mechanism. The metabolic research landscape currently features three tiers of incretin-based compounds:
| Approach | Receptors | Examples |
|---|---|---|
| Mono-agonist | GLP-1R only | Semaglutide, liraglutide |
| Dual agonist | GLP-1R + GIPR | Tirzepatide |
| Triple agonist | GLP-1R + GIPR + GCGR | GLP3-RT |
Each tier has demonstrated progressively larger effect sizes in clinical research. But the jump from dual to triple isn't just about "more receptors = more effect." The glucagon receptor introduces a fundamentally different mechanism.
Mono- and dual agonists primarily reduce caloric intake. They make subjects eat less. That's powerful, but it only addresses one variable in the energy balance equation.
Triple agonism adds increased energy expenditure. GLP3-RT doesn't just reduce what goes in — it increases what gets burned. The glucagon-driven thermogenesis and hepatic fat oxidation represent a second axis of metabolic impact that prior compounds couldn't access.
This dual-lever mechanism is particularly relevant for liver fat research. GLP-1 mono-agonists have shown modest effects on hepatic steatosis. Dual agonists improve on this. But GLP3-RT's Phase 2 data showed dramatic liver fat reductions — a direct consequence of glucagon receptor-mediated hepatic fat oxidation acting locally in the organ where fat accumulates.
For researchers modeling metabolic dysfunction, the triple-agonist approach allows investigation of multi-pathway interventions that no combination of single-target compounds can perfectly replicate. The pharmacokinetics, receptor engagement ratios, and downstream signaling cascades of a unified triple-agonist molecule differ meaningfully from co-administering three separate peptides.
Published Research: Phase 2 Clinical Trial Results
The pivotal data on GLP3-RT comes from a Phase 2, randomized, double-blind, placebo-controlled trial published in peer-reviewed literature.
Jastreboff et al. (2023) — New England Journal of Medicine
"Triple-Hormone-Receptor Agonist GLP3-RT (LY-3437943) for Obesity — A Phase 2 Trial"
This 48-week study enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized across multiple GLP3-RT dose arms or placebo.
Key findings:
- 24.2% mean body weight reduction at the highest dose arm over 48 weeks
- Over 25% of participants at the highest dose lost more than 30% of baseline body weight
- Dose-dependent response across all arms
- At the time of publication, this represented the largest mean body weight reduction reported for any single investigational agent in a clinical trial
Hepatic Fat Sub-Analysis — Jastreboff et al. (2023)
A companion analysis from the same Phase 2 trial examined liver fat content:
- Up to 86% reduction in liver fat from baseline at the highest dose
- Over 80% of participants with MASLD (metabolic dysfunction-associated steatotic liver disease) achieved complete resolution of hepatic steatosis at 48 weeks
- These results substantially exceeded outcomes observed with GLP-1 mono-agonists in comparable liver fat studies
Rosenstock et al. (2023) — New England Journal of Medicine
Secondary metabolic endpoints from the Phase 2 program showed:
- HbA1c reduction of approximately 1.3% across dose arms
- Significant reductions in fasting glucose, triglycerides, and systolic blood pressure
- Broad metabolic improvement profile suggesting multi-organ impact beyond adipose tissue
Urva et al. (2022) — The Lancet
The Phase 1 dose-escalation trial in participants with type 2 diabetes established:
- Dose-dependent reductions in body weight and HbA1c
- Acceptable tolerability across escalation cohorts
- Proof of concept for the triple-agonist mechanism in humans
- Gastrointestinal side effects (nausea, vomiting, diarrhea) as the primary tolerability signal, consistent with the GLP-1 agonist class
All clinical data referenced here comes from published, peer-reviewed literature. GLP3-RT remains investigational and is not approved for any therapeutic use. All Ki Peptides GLP3-RT is sold for research use only.
Research Applications
GLP3-RT's triple-receptor mechanism makes it a versatile tool compound for several research domains:
Metabolic syndrome modeling — Investigating the interplay between incretin signaling, glucagon-driven thermogenesis, and insulin sensitivity in multi-receptor paradigms.
Hepatic steatosis / MASLD research — The dramatic liver fat reductions observed in Phase 2 make GLP3-RT particularly relevant for researchers studying non-alcoholic fatty liver models and hepatic lipid metabolism.
Body composition studies — Examining the differential effects of combined appetite suppression and increased energy expenditure on fat mass versus lean mass preservation.
Comparative pharmacology — Studying the mechanistic differences between mono- (GLP-1), dual- (GLP-1/GIP), and triple-agonist (GLP-1/GIP/glucagon) approaches in controlled research settings.
Cardiovascular risk marker research — The Phase 2 data showed improvements in blood pressure, triglycerides, and glucose markers, making GLP3-RT useful for researchers studying metabolic contributions to cardiovascular risk profiles.
Energy expenditure mechanisms — Investigating how glucagon receptor activation drives hepatic thermogenesis and whether this mechanism operates independently of or synergistically with incretin-mediated appetite effects.
Storage
- Store lyophilized product at -20°C for long-term or 2–8°C for up to 12 months
- Protect from light. Avoid repeated freeze-thaw cycles.
Complementary Research Compounds
Researchers frequently study GLP3-RT alongside complementary compounds:
- GLP3-RT + Tesamorelin — Triple-agonist effects paired with GH-driven visceral fat reduction
- GLP3-RT + MOTS-C — Receptor-level metabolic modulation combined with mitochondrial energy optimization
- GLP3-RT + Ipamorelin/CJC-1295 — Fat reduction alongside GH-supported lean mass preservation
Frequently Asked Questions
What is GLP3-RT?
GLP3-RT (LY-3437943) is a synthetic peptide designed as the first triple-incretin receptor agonist. It simultaneously activates GLP-1, GIP, and glucagon receptors in a single molecule. It is currently in Phase 3 clinical trials and is available for research use only.
How is GLP3-RT different from semaglutide and tirzepatide?
Semaglutide is a GLP-1 mono-agonist — it targets one receptor. Tirzepatide is a dual GLP-1/GIP agonist — two receptors. GLP3-RT activates all three: GLP-1, GIP, and glucagon. The addition of glucagon receptor agonism introduces hepatic fat oxidation and increased energy expenditure mechanisms that the other compounds do not directly engage.
What were the key Phase 2 results for GLP3-RT?
The Phase 2 trial (Jastreboff et al., 2023, NEJM) showed a 24.2% mean body weight reduction at the highest dose (12mg) over 48 weeks. The liver fat sub-analysis showed up to 86% reduction in hepatic fat, with over 80% of MASLD participants achieving complete steatosis resolution.
Why does GLP3-RT include glucagon receptor activation?
Glucagon drives hepatic thermogenesis and fat oxidation — it increases energy expenditure. While GLP-1 and GIP primarily reduce caloric intake, glucagon activation addresses the output side of the energy equation. The combination targets both intake and expenditure simultaneously.
How should GLP3-RT be stored?
Store lyophilized GLP3-RT at -20°C for long-term storage or refrigerated (2–8°C) for up to 12 months. Protect from light and avoid repeated freeze-thaw cycles.
Is GLP3-RT approved for therapeutic use?
No. GLP3-RT is currently in Phase 3 clinical trials and has not received regulatory approval for any therapeutic indication. All GLP3-RT sold by Ki Peptides is for research use only.
Where can I purchase research-grade GLP3-RT?
Ki Peptides supplies GLP3-RT at ≥99% purity (HPLC-verified) with third-party testing and a Certificate of Analysis (COA) included with every order. Shop GLP3-RT 20mg.
Sources
-
Jastreboff, A.M., Kaplan, L.M., Frias, J.P., et al. (2023). "Triple-Hormone-Receptor Agonist GLP3-RT for Obesity — A Phase 2 Trial." New England Journal of Medicine, 389(6), 514–526.
-
Rosenstock, J., Frias, J.P., Jastreboff, A.M., et al. (2023). "GLP3-RT, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled and Active-Comparator-Controlled Phase 2 Trial." The Lancet, 402(10401), 529–544.
-
Urva, S., Coskun, T., Loh, M.T., et al. (2022). "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1, randomised, double-blind, placebo-controlled and active comparator-controlled trial." The Lancet, 400(10366), 1869–1881.
-
Coskun, T., Urva, S., Roell, W.C., et al. (2022). "LY3437943, a novel triple glucagon, GIP, GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism, 34(9), 1234–1247.
This article is for educational and informational purposes only. GLP3-RT is sold as a research chemical and is not intended for human therapeutic use. Ki Peptides does not make any claims regarding the treatment, cure, or prevention of any disease. All references to clinical trials reflect published research findings and do not constitute medical advice. For research use only.